Pramlintide
Pramlintide (Symlin)
Pramlintide is a synthetic analog of human amylin, a pancreatic hormone co-secreted with insulin by beta cells, approved by the FDA as an adjunct to mealtime insulin therapy in adults with type 1 or type 2 diabetes. It is used to improve postprandial glucose control, reduce mealtime insulin requirements, and modestly promote weight loss by slowing gastric emptying and suppressing glucagon secretion.
Mechanism of Action
Pramlintide acts as an amylin receptor agonist, binding to calcitonin receptor-based amylin receptor complexes (AMY1, AMY2, AMY3) in the area postrema, hypothalamus, and nucleus accumbens. It suppresses postprandial glucagon secretion from pancreatic alpha cells, slows gastric emptying to blunt postprandial glucose excursions, and promotes satiety signaling centrally, collectively reducing mealtime glucose spikes without directly stimulating insulin secretion.
Evidence by Health Goal(18 goals)
Dosing Protocols
Immediately before each major meal containing at least 250 kcal or 30g of carbohydrates
Type 1: initiate at 15mcg per meal, titrate by 15mcg increments every 3 days as tolerated up to 30-60mcg. Type 2: initiate at 60mcg per meal, titrate to 120mcg if tolerated after 3-7 days. Reduce mealtime insulin dose by 50% at initiation to minimize hypoglycemia risk. Inject subcutaneously into abdomen or thigh; do NOT mix with insulin in the same syringe.
Safety & Side Effects
Pramlintide carries an FDA black box warning regarding severe hypoglycemia when used concomitantly with insulin, particularly in type 1 diabetes patients; insulin dose reduction and careful glucose monitoring are mandatory at initiation. It is a prescription-only medication in the United States and most countries, and is contraindicated in patients with hypoglycemia unawareness, gastroparesis, or confirmed hypersensitivity to amylin analogs or metacresol.
Possible Side Effects
- !Nausea (most common, occurring in up to 48% of patients, typically dose-dependent and diminishing over weeks)
- !Hypoglycemia (especially severe hypoglycemia within 3 hours of injection when mealtime insulin is not reduced)
- !Vomiting, particularly during initial titration phase
- !Anorexia and reduced appetite (also responsible for modest weight loss benefit)
- !Injection site reactions including erythema, bruising, or mild local discomfort
- !Headache reported in approximately 13% of type 2 patients in clinical trials
- !Fatigue and dizziness, particularly in the context of hypoglycemic episodes
- !Abdominal pain or cramping due to slowed gastric motility
Interactions
- -Additive hypoglycemia risk with mealtime insulin — mandatory 50% mealtime insulin dose reduction required at initiation
- -Delays oral drug absorption due to slowed gastric emptying — time-sensitive medications (e.g., analgesics, antibiotics) should be taken 1 hour before or 2 hours after pramlintide
- -May potentiate hypoglycemic effects of sulfonylureas, meglitinides, and other insulin secretagogues — monitor blood glucose closely
- -Concurrent use with anticholinergic agents (e.g., certain antihistamines, antidepressants) may unpredictably alter gastric emptying and compound GI side effects
- -Alpha-glucosidase inhibitors (acarbose, miglitol) have additive effects on slowing carbohydrate absorption — combined use is generally not recommended due to compounding GI adverse effects
Cost & Where to Buy
Pramlintide (Symlin) is available only as a brand-name prescription product in the US with no generic equivalent; cost varies significantly based on insurance coverage, dose, and meal frequency. Manufacturer savings cards may reduce out-of-pocket costs substantially for eligible patients. Compounded versions may be available at lower cost through select compounding pharmacies.
Search on Amazon